Coherus BioSciences Inc CHRS:NASDAQ

Last Price$13.86Cboe Real-Time Last Sale as of 3:03PM ET 8/15/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.10(0.73%)
Bid (Size)$13.84 (300)
Ask (Size)$13.87 (100)
Day Low / High$13.34 - 13.97
Volume604.8 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/15/2022


Coherus BioSciences Inc ( NASDAQ )

Price: $13.86
Change: +0.10 (0.73%)
Volume: 604.8 K
3:03PM ET 8/15/2022

MannKind Corp ( NASDAQ )

Price: $4.07
Change: -0.08 (2.05%)
Volume: 2.0 M
3:02PM ET 8/15/2022

Crinetics Pharmaceuticals Inc ( NASDAQ )

Price: $21.79
Change: +1.24 (6.03%)
Volume: 395.8 K
3:00PM ET 8/15/2022

Innoviva Inc ( NASDAQ )

Price: $14.56
Change: -0.18 (1.22%)
Volume: 159.6 K
3:00PM ET 8/15/2022

Aclaris Therapeutics Inc ( NASDAQ )

Price: $16.85
Change: +0.05 (0.30%)
Volume: 126.3 K
3:02PM ET 8/15/2022

Read more news Recent News

-- Earnings Flash (CHRS) COHERUS BIOSCIENCES Reports Q2 Revenue $60.2M
4:10PM ET 8/04/2022 MT Newswires


-- Earnings Flash (CHRS) COHERUS BIOSCIENCES Reports Q2 Loss $-0.47
4:10PM ET 8/04/2022 MT Newswires


Coherus BioSciences Receives FDA Approval for Lucentis Biosimilar; Shares Rise Pre-Bell
5:16AM ET 8/03/2022 MT Newswires

Coherus BioSciences (CHRS) said Tuesday the US Food and Drug Administration approved its retinal disease drug Cimerly as an interchangeable biosimilar to...

Coherus BioSciences Says FDA Accepts Resubmission of Biologics License Application for Cancer Treatment
9:16AM ET 7/06/2022 MT Newswires

Coherus BioSciences (CHRS) and partner Shanghai Junshi Biosciences Co. said Wednesday the US Food and Drug Administration has accepted for review a...

Company Profile

Business DescriptionCoherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA. View company web site for more details
Address333 Twin Dolphin Drive
Redwood City, California 94065
Number of Employees232
Recent SEC Filing08/04/202210-Q
Chairman, President & Chief Executive OfficerDenny M. Lanfear
Chief Financial OfficerMcDavid Stilwell
Chief Scientific OfficerVladimir Vexler
Chief Technical OfficerRichard L. Hameister

Company Highlights

Price Open$13.68
Previous Close$13.76
52 Week Range$5.60 - 19.32
Market Capitalization$1.1 B
Shares Outstanding77.7 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/14/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.92
Beta vs. S&P 500N/A
Net Profit Margin-83.47%
Return on Equity-422.10%

Analyst Ratings as of 06/13/2022

Consensus RecommendationConsensus Icon
Powered by Factset